丙二酰脒盐酸盐 | 34570-17-7

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 丙二酰脒盐酸盐
• 中文别名: α-脒基乙酰胺盐酸盐；Alpha-脒基乙酰胺盐酸盐；乙酰胺脒盐酸盐；乙酸胺脒盐酸盐
• 英文名称: malonamamidine hydrochloride
• 英文别名: malonamidine hydrochloride；(3-amino-3-oxopropanimidoyl)azanium;chloride
• CAS: 34570-17-7
• 化学式: C₃H₇N₃O*ClH
• mdl: MFCD00013007
• 分子量: 137.569
• InChiKey: MPRLIYNSZYJODI-UHFFFAOYSA-N

物化性质

• 熔点：
  174-176 °C(lit.)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，也未有已知的危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.88
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  93
• 氢给体数：
  4
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

Name:	Malonamamidine hydrochloride 99% Material Safety Data Sheet
Synonym:	None listed
CAS:	34570-17-7

Section 1 - Chemical Product MSDS Name:Malonamamidine hydrochloride 99% Material Safety Data Sheet
Synonym:None listed

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
34570-17-7	Malonamamidine hydrochloride	99	252-095-5

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Wash area with soap and water. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 34570-17-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 174.00 - 176.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C3H7N3O.HCl
Molecular Weight: 137.57

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 34570-17-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Malonamamidine hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 34570-17-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 34570-17-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 34570-17-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

氨基琥胺盐酸盐是一种化学试剂，用于制备用作DGAT1抑制剂的嘧啶噁嗪类药物。这种药物有可能作为减肥治疗的候选药物。

反应信息

• 作为反应物：
  描述：

  丙二酰脒盐酸盐 、 乙酰丙酮 在 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以79%的产率得到2-氨基-4,6-二甲基-3-吡啶甲酰胺
  参考文献：
  名称：

  发现一系列在血管紧张素II 1型受体和过氧化物酶体增殖物激活的受体-γ上具有双重活性的咪唑并[4,5- b ]吡啶

  摘要：

  内部收集血管紧张素II 1型受体拮抗剂以鉴定对过氧化物酶体增殖物激活受体-γ（PPARγ）具有活性的化合物，发现了一系列新的咪唑并[4,5- b ]吡啶2在这些化合物上具有活性两个受体。与人PPARγ的配体结合域结合的前导化合物2a的晶体结构的早期可用性证实了该支架与核受体的相互作用方式，并有助于优化PPARγ活性。在新化合物中，（S）-3-（5-（2-（1 H-四唑-5-基）苯基）-2,3-二氢-1 H-茚满-1-基）-2-乙基- 5-异丁基-7-甲基-3 H-咪唑[4,5- b对吡啶（2l）被确定为有效的血管紧张素II型I受体阻滞剂（IC 50 = 1.6 nM），具有部分PPARγ激动作用（EC 50 = 212 nM，最大31％），并且在大鼠中具有口服生物利用度。在高血压（SHR）和胰岛素抵抗（ZDF大鼠）的动物模型中证实了2l的双重药理学。在SHR中，2l在降低血压方面非常有效，

  DOI：

  10.1021/jm200409s
• 作为产物：
  描述：

  β-乙氧基-β-亚氨基丙酸乙酯 在 乙醇 、 氨 作用下， 生成 丙二酰脒盐酸盐
  参考文献：
  名称：

  Shaw; Woolley, Journal of Biological Chemistry, 1949, vol. 181, p. 89,91

  摘要：

  DOI：

文献信息

• TNF -Alpha Modulating Benzimidazoles
  申请人：UCB Biopharma SPRL

  公开号：US20150152065A1

  公开（公告）日：2015-06-04

  A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列苯并咪唑衍生物，作为人类肿瘤坏死因子α活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis
  作者：Wolfgang Miltz、Juraj Velcicky、Janet Dawson、Amanda Littlewood-Evans、Marie-Gabrielle Ludwig、Klaus Seuwen、Roland Feifel、Berndt Oberhauser、Arndt Meyer、Daniela Gabriel、Mark Nash、Pius Loetscher

  DOI：10.1016/j.bmc.2017.06.050

  日期：2017.8

  extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.

  GPR4是一种G蛋白偶联受体，起质子传感器的作用，可被细胞外酸性pH激活，并被认为在与多种炎性疾病相关的酸中毒中起着关键作用。从高通量筛选命中1开始，开发了一种口服活性GPR4拮抗剂39c。该化合物显示出有效的细胞活性，并且在血管生成，炎症和疼痛的动物模型中有效。
• Synthesis of Multisubstituted 2-Aminopyrroles/pyridines via Chemoselective Michael Addition/Intramolecular Cyclization Reaction
  作者：Xueyu Qi、Haoyue Xiang、Qian He、Chunhao Yang

  DOI：10.1021/ol5018855

  日期：2014.8.15

  A facile and efficient synthetic strategy to construct polysubstituted 2-aminopyrroles/pyridines was developed via chemoselective Michael addition/intramolecular cyclization reaction under very mild conditions. It suggested that the chemoselectivity of the process could be controlled by the leaving ability of the halides.

  通过在非常温和的条件下通过化学选择性迈克尔加成/分子内环化反应，开发了一种构建多取代的2-氨基吡咯/吡啶的简便有效的合成策略。这表明该过程的化学选择性可以通过卤化物的离去能力来控制。
• Synthesis of new 2-substituted pyrido[2,3-d]pyrimidin-4(1H)-ones and their antibacterial activity☆
  作者：B. Lakshmi Narayana、A. Raghu Ram Rao、P. Shanthan Rao

  DOI：10.1016/j.ejmech.2008.05.025

  日期：2009.3

  2-Substituted-5,7-dimethyl pyrido[2,3-d]pyrimidin-4(1H)-ones (8) were synthesized by oxidation of 2-substituted-5,7-dimethyl dihydropyrido[2,3-d]pyrimidin-4(1H)-ones (7) which were in turn prepared from 2-amino-4,6-dimethyl nicotinamide (5) and substituted aryl aldehydes (6). 2-Amino-4,6-dimethyl nicotinamide (5) was prepared from ethyl cyanoacetate (1) via malonamamidine hydrochloride (3). The compounds

  2-取代的-5,7-二甲基吡啶并[2,3- d ]嘧啶-4（1 ħ） -酮（8）通过2-取代-5,7-二甲基二氢吡啶氧化并[2,3-合成d ]嘧啶-4（1 H）-一（7），其依次由2-氨基-4,6-二甲基烟酰胺（5）和取代的芳基醛（6）制备。由氰基乙酸乙酯（1）通过丙二酸ama丙啶（3）制备2-氨基-4,6-二甲基烟酰胺（5）。通过IR，NMR，MS和元素分析对化合物进行表征。化合物7和8筛选针对革兰氏阳性和阴性细菌的抗菌活性。脱氢化合物（8）的抗菌活性低于化合物7。在所有筛选的具有抗菌活性的化合物中，7c（1.25μg/ ml）表现出更高的活性。当在200μg/ ml的浓度下筛选抗真菌活性时，发现所有合成的化合物均无活性。
• 一种阿折地平杂质及其制备方法
  申请人：青岛科技大学

  公开号：CN108707106A

  公开（公告）日：2018-10-26

  本发明属于阿折地平杂质制备领域，公开了一种阿折地平杂质及其制备方法。该方法以阿折地平关键中间体为原料，通过有机铵盐和有机铝试剂氨解，得到丙二酰脒盐，再与阿折地平关键中间体发生Hantzsch缩合，定向合成得到纯度高的阿折地平氨解杂质。本发明提供的制备方法反应条件温和、简单易操作，目标产物容易分离、产物收率和纯度较高；制备得到的阿折地平杂质明确后能够准确反应其在原料药中的准确含量，同时该已知杂质可以定向合成杂质对照品，可以以外标法等计算出杂质在原料药中的准确含量，对控制原料药的纯度有积极意义。